45th week of 2009 patent applcation highlights part 29 |
Patent application number | Title | Published |
20090274707 | Anti-IL-12 Antibodies, Nucleic Acids Encoding Antibodies, and Methods of Production - Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders. | 2009-11-05 |
20090274708 | Recombinant Toxin Fragments - Antigenic compositions are provided comprising a single chain polypeptide comprising first and second domains, wherein said first domain is a clostridial neurotoxin light chain or a fragment or a variant thereof and is capable of cleaving one or more vesicle or plasma membrane associated proteins essential to exocytosis; and said second domain is a clostridial neurotoxin heavy chain H | 2009-11-05 |
20090274709 | Lipocalin-2 As A Prognostic and Diagnostic Marker For Heart And Stroke Risks - Methods and apparatus are disclosed for the measurement of lipocalin-2 in body fluids (including but not limited to blood, serum, plasma, urine, saliva, tear, etc.) by an assay such as an immunoassay or an immunotest for (1) the prediction of risk of future cardiovascular diseases; and (2) the determination of the likelihood that certain individuals will benefit to a greater or lesser extent from the use of certain treatments designed to prevent and/or treat cardiovascular diseases. | 2009-11-05 |
20090274710 | TRANS-MEMBRANE-ANTIBODY INDUCED INHIBITION OF APOPTOSIS - Cell suicide (apoptosis) is associated with pathogenesis, for example, it is the major cause for the loss of neurons in Alzheimer's disease. Caspase-3 is critically involved in the pathway of apoptosis. Superantibody (SAT)-trans-membrane technology has been used to produce antibodies against the caspase enzyme in an effort to inhibit apoptosis in living cells. The advantage of using trans-membrane antibodies as apoptosis inhibitors is their specific target recognition in the cell and their lower toxicity compared to conventional apoptosis inhibitors. It is shown that a MTS-transport-peptide modified monoclonal anti-caspase-3 antibody reduces actinomycin D-induced apoptosis and cleavage of spectrin in living cells. These results indicate that antibodies conjugated to a membrane transporter peptide have a therapeutic potential to inhibit apoptosis in a variety of diseases. | 2009-11-05 |
20090274711 | LEVELS OF BLyS/APRIL HETEROTRIMERS IN SERUM AND USE IN DIAGNOSTIC METHODS - The present invention provides a method of measuring the levels of BLyS/APRIL heterotrimers (HT) in a biological sample, in a preferred embodiment, in serum. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with HT antagonists, either singly or in combination with other immune suppressive drugs. | 2009-11-05 |
20090274712 | COMPOSITIONS FOR COATING CELL MEMBRANES AND METHODS OF USE THEREOF - In certain aspects, the invention relates to cell delivery compositions comprising a progenitor cell and a targeting moiety, and methods related thereto. Such compositions and methods may be used, for example, in administering a targeted cell therapy cell therapy to a subject. | 2009-11-05 |
20090274713 | CROSS-LINKERS AND THEIR USES - Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same. | 2009-11-05 |
20090274714 | TUMOUR-ASSOCIATED PEPTIDES BINDING TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I OR II MOLECULES AND RELATED ANTI-CANCER VACCINE - The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to two novel peptide sequences derived from HLA class II molecules of human tumour cell lines, which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 2009-11-05 |
20090274715 | TICK CHITINASE - A novel chitinase, a polynucleotide encoding the same, a vector and a transformant comprising the polynucleotide, an antibody against the chitinase, and a screening method for screening a substance capable of modifying the chitinase, are disclosed. According to the chitinase, polynucleotide, or vector, it is possible, for example, to exterminate ticks, or to treat or prevent tick-borne infections such as piroplasmosis, Q fever, or viral encephalitis. | 2009-11-05 |
20090274716 | LAGE-1 TUMOR ASSOCIATED NUCLEIC ACIDS - The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product. | 2009-11-05 |
20090274717 | Genes and proteins, and their use - According to the present invention, a series of genes are identified in Group B | 2009-11-05 |
20090274718 | CHIMERIC PROTEINS THAT INDUCE EFFECTS DIRECTED AGAINST VIRUSES - The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from | 2009-11-05 |
20090274719 | CHLAMYDIA TRACHOMATIS GENOMIC SEQUENCE AND POLYPEPTIDES, FRAGMENTS THEREOF AND USES THEREOF, IN PARTICULAR FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF INFECTION - The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of | 2009-11-05 |
20090274720 | Anti-dementia substance from hericium erinaceum and method of extraction - A fat-soluble fraction extracted from the fruiting body of | 2009-11-05 |
20090274721 | Compositions Comprising Hypsizygus Ulmarius Extract - Disclosed are topical compositions comprising extracts of | 2009-11-05 |
20090274722 | Therapeutic Composition for the Treatment of BPH and ED - The invention relates to a therapeutic composition for the prevention and/or treatment of Benign Prostatic Hyperplasia (BPH) and other related prostate problems. The invention is a therapeutic composition that combines alfalfa and fennel to have a synergistic effect for the treatment of prostate problems, erectile dysfunction, and/or sleep disorders. The composition may further include ginger, red Reishi mushroom and oyster mushroom. | 2009-11-05 |
20090274723 | Modified vaccinia ankara virus vaccine - The present invention relates, in general, to vaccines and, in particular, to a modified vaccinia Ankara (MVA) virus, to a composition comprising such a virus and to methods of using same to induce an immune response. | 2009-11-05 |
20090274724 | NOVEL RECOMBINANT AND MUTANT ADENOVIRUSES - The present invention provides novel viral vectors. In one embodiment, the present invention provides mutant and recombinant bovine adenoviruses having a deletion and/or insertion of DNA in the early gene region 4 (E4). In another embodiment, the present invention provides mutant and recombinant bovine adenovirus 1 viruses having a deletion and/or insertion of DNA in the early gene region 3 (E3). The present invention also contemplates the use of the viral vectors for vaccination, gene therapy or other applications as suitable. | 2009-11-05 |
20090274725 | Materials and Methods for Detecting, Preventing, and Treating Retroviral Infection - The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans. | 2009-11-05 |
20090274726 | SYNTHETIC GENE - The present invention relates to synthetic genes, processes for designing said synthetic genes and their uses in gene therapy and improved DNA vaccination. The novel synthetic genes and processes are codon shuffled so that they have reduced homology relative to a naturally occurring gene encoding the same protein without altering the overall codon usage frequency of the gene. In particular the present invention relates to improved polynucleotides and methods for the treatment or prevention of disease comprising codon-shuffled GM-CSF nucleic acid sequences. Nucleic acid vaccines of the present invention may comprise a combination of a nucleotide sequence encoding codon-shuffled GM-CSF, a nucleotide encoding an antigen against which it is desired to raise an immune response and a toll-like receptor (TLR) agonist. | 2009-11-05 |
20090274727 | Recombinant RSV Virus Expression Systems And Vaccines - The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene. | 2009-11-05 |
20090274728 | Mutant Viruses - An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses. | 2009-11-05 |
20090274729 | MEDIA FOR CLOSTRIDIUM BACTERIUM AND PROCESSES FOR OBTAINING A CLOSTRIDIAL TOXIN - Animal product free (APF) media and processes for the culture and fermentation of botulinum toxin producing | 2009-11-05 |
20090274730 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION - Provided are electrokinetically-generated fluids (e.g., gas-enriched electrokinetic fluids or solutions), and therapeutic compositions and methods for use in treating inflammation or at least one symptom of inflammation. The electrokinetically-generated fluids or therapeutic compositions and methods include electrokinetically-generated aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-generated fluids (e.g., electrokinetically-generated gas-enriched fluids and solutions) and therapeutic compositions. | 2009-11-05 |
20090274731 | PRODUCTION OF ENVELOPED PHARMACEUTICAL DOSAGE FORMS - A process for at least partially enveloping a pharmaceutical dosage form, in which the dosage form is surrounded by a shrinkable film, and the film is subsequently shrunk is described. | 2009-11-05 |
20090274732 | Type-2 Diabetes Combination Wafer - Rapidly disintegrating oral dosage forms for the application of active agent combinations for diabetes therapy. The dosage forms contain at least two active agents suitable for treating type-2 diabetes. The antidiabetic active agents are selected from the group comprising sulfonylureas, glitazones, glinides, biguanides, and absorption-delaying agents. The use of the active agent combination to produce an oral dosage form for the treatment of diabetes, a method for the therapeutic treatment of diabetes, and a method for the production of a sheet-like dosage form are also disclosed. | 2009-11-05 |
20090274733 | Pharmaceutical preparation containing copolyvidone - A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated. | 2009-11-05 |
20090274734 | METHOD FOR OBTAINING HOLLOW PARTICLES - Described is a method for obtaining hollow particles, having a particle wall and a particle lumen, the particle having dimensions of between 1 nm and 100 μm, from a mixture comprising a liquid medium comprising at least one colloid or solute, the method comprising freezing said mixture and lyophilising the obtained frozen mixture, characterised in that a volume of at least 0.1 μl of the mixture is subjected to a freezing step comprising: (a) (1) quench freezing the mixture resulting in a quench frozen mixture, and (2) incubating said quench frozen mixture at a temperature above the quench freezing temperature and below the melting point of the liquid medium, orb) (1) reducing the temperature of the mixture at a rate of 1 to 100° C./minute to below the freezing temperature of the mixture and (2) incubating said frozen mixture at a temperature above the temperature of the mixture and below the melting point of the liquid medium. Further, hollow particles obtainable by the said method, compositions comprising said hollow particles and uses thereof are described. | 2009-11-05 |
20090274735 | Flaky Particles and Luster Pigment, and Cosmetic, Coating Composition, Resin Composition and Ink Composition Each Containing the Same - Flaky particles of the present invention have a particle size distribution in which a value of D90/D10 is at least 2.0 but not more than 3.0, a value of D10 is at least 4.7 μm but not more than 25 μm, and a maximum particle diameter is 90 μm or less, where D10 is defined as a particle diameter at which a cumulative volume of particles reaches 10% when counted from the smaller side, and D90 is defined as a particle diameter at which a cumulative volume of particles reaches 90% when counted from the smaller side. A luster pigment of the present invention contains flaky particles and at least one selected from a metallic layer and a metallic oxide layer that are formed on at least a part of the surface of each of the flaky particles. The luster pigment has a particle size distribution in which a value of D90/D10 is at least 2.0 but not more than 3.0, a value of D10 is at least 4.7 μm but not more than 25 μm, and a maximum particle diameter is 90 μm or less, where D10 is defined as a particle diameter at which a cumulative volume of particles reaches 10% when counted from the smaller side, and D90 is defined as a particle diameter at which a cumulative volume of particles reaches 90% when counted from the smaller side. | 2009-11-05 |
20090274736 | Nutraceutical Compositions From Microalgae And Related Methods of Production And Administration - Provided herein are polysaccharide compositions and methods of culturing microalgae to produce polysaccharides. Also provided are methods of using polysaccharides for applications such as reducing cholesterol in mammals, inactivating viruses, stabilizing foods, and other uses. Also provided are transgenic algae capable of utilizing fixed carbon sources for energy. Also provided herein are novel nucleic acid sequences from red microalgae. | 2009-11-05 |
20090274737 | IMPLANT COMPRISING A SURFACE OF REDUCED THROMBOGENICITY - An implant for a human or animal body, comprising a surface having reduced thrombogenic properties, whose surface has a wetting angle of Θ, where Θ≦80°. Also disclosed is a method for producing an implant and the use an implant to reduce the dose or concentration in administration of a concomitant systemic medication with one or more anticoagulant active ingredients before, during or after implantation of the implant in a human or animal body. | 2009-11-05 |
20090274738 | IMPLANTABLE DEVICES FOR PROMOTING REENDOTHELIALIZATION AND METHODS OF USE THEREOF - An implantable device for the controlled delivery of an estrogen receptor agonist to an injured site in the lumen of a mammalian blood vessel, wherein the estrogen receptor agonist is present in an amount of at least about 16.7 μg/mm implantable device length. Methods of use thereof. | 2009-11-05 |
20090274739 | METHODS AND COMPOSITIONS FOR TREATING NEOINTIMAL HYPERPLASIA - The present invention relates to compositions containing an mTOR inhibitor, such as rapamycin or a rapamycin derivative, in combination with a PI3 kinase inhibitor and/or a leptin inhibitor, intraluminal devices configured to release such compositions, and methods for the treatment and/or prevention of intimal hyperplasia, vascular stenosis and/or restenosis comprising delivery of such compositions or intraluminal devices to subjects in need thereof. The compositions, intraluminal devices, and methods of the invention are particularly well-suited for the treatment or prevention of vascular stenosis and restenosis in obese and diabetic subjects. | 2009-11-05 |
20090274740 | DRUG-LOADED MEDICAL DEVICES AND METHODS FOR MANUFACTURING DRUG-LOADED MEDICAL DEVICES - Drug-loaded medical devices such as stents and methods for manufacturing them are provided. In certain embodiments, the therapeutic agent is loaded only in or on areas of the medical device that do not undergo substantial deformation during expansion. The medical device may be provided with reservoirs in or on the first portions of the medical device that do not undergo substantial deformation during expansion, and the therapeutic agent may be loaded in these reservoirs. The reservoirs may be covered with a porous coating which may be a non-polymeric coating. In other embodiments, a non-polymeric coating is provided in a discontinuous manner in or on the medical device. A method includes the steps of providing a transfer member that includes a translucent substrate and a layer of transfer material such as a film or foil; attaching reservoirs to the transfer material; positioning the transfer member with the reservoirs adjacent a medical device, such as a stent, with the reservoirs facing the medical device; and directing a laser beam at the transfer member such that the laser beam passes through the translucent substrate to vaporize a portion of the transfer material, creating a pocket of trapped gas between the translucent substrate and reservoir, thereby forcing the reservoir from the transfer member to the medical device. The reservoirs may be formed of a non-polymeric material. | 2009-11-05 |
20090274741 | POLYMERS CONTAINING POLY(ESTER AMIDES) AND AGENTS FOR USE WITH MEDICAL ARTICLES AND METHODS OF FABRICATING THE SAME - Polymers containing poly(ester amides) and agents for use with medical articles and methods of fabricating the same are disclosed. The medical article generally comprises an implantable substrate having a coating, and the coating contains a polymer comprising a polymeric product of a reaction comprising a polyol, a polycarboxylic acid, an amino acid and an agent. | 2009-11-05 |
20090274742 | MULTIMODAL HIGH STRENGTH DEVICES AND COMPOSITES - An oriented implantable biodegradable multimodal device is disclosed. The orientated implantable biodegradable multimodal device includes a blend of a first polymer component having a first molecular weight (mwt) together with at least a second polymer component having a mwt which is less than that of the first component. The polymer within the blend may be in a uniaxial, biaxial or triaxial orientation. Also disclosed is a composite thereof with matrix polymer, processes for the preparation thereof and the use thereof as an implantable biodegradable device such as a high strength trauma fixation device suitable for implantation into the human or animal body. As examples the high strength trauma device may take the form of plates, screws, pins, rods, anchors or scaffolds. | 2009-11-05 |
20090274743 | MEDICAL DEVICES HAVING A BIORESORBABLE COATING LAYER WITH A PRE-DETERMINED PATTERN FOR FRAGMENTATION - Intravascular medical devices comprising a coating layer disposed on a substrate associated with the medical device, wherein the coating layer has a pre-determined fragmentation pattern. At least a portion of the coating layer comprises a plurality of discontinuous bioresorbable members, wherein the discontinuous bioresorbable members have a size less than the luminal diameter of an arteriole. The coating layer may be formed by excavating portions of a coating layer (e.g., by laser ablation) to create gaps which define the discontinuous bioresorbable members. In certain embodiments, the coating layer is formed of a heat-bondable material. In such embodiments, the discontinuous bioresorbable members may be adhered to the substrate via heat bonds. Also disclosed are methods of forming a coating layer on medical devices and methods of treating intravascular sites. | 2009-11-05 |
20090274744 | Drug delivery system based on cationic siloxanyl macromonomers - Matrix controlled diffusion drug delivery systems are described herein which are based on one or more silicon-containing monomers of the general formula: | 2009-11-05 |
20090274745 | Drug delivery systems based on catonic siloxanyl macromonomers - Matrix controlled diffusion drug delivery systems based on one or more silicon-containing monomers of the general formula: | 2009-11-05 |
20090274746 | METHODS AND COMPOSITIONS FOR CONTROLLED DELIVERY OF PHYTOCHEMICAL AGENTS - The presently-disclosed subject matter provides compositions and methods for treating a cancer by providing a composition comprising a biocompatible polymeric matrix incorporating an effective amount of a phytochemical agent, a combination of phytochemical agents, or a phytochemical agent and a chemotherapeutic agent. Further, provided is a device for uterine cervical insertion for local delivery. | 2009-11-05 |
20090274747 | Pressure-Sensitive Adhesive Base and Medical Adhesive Patch Including the Pressure-Sensitive Adhesive Base - A pressure-sensitive adhesive base which contains the liquid organic ingredient and which, despite this, has moderate pressure-sensitive adhesion properties (tackiness and cohesive force) and causes no bleeding. It hardly injures the keratin of the skin and is inhibited from irritating the skin. The pressure-sensitive adhesive base comprises the following ingredients (A) to (C): (A) a copolymer comprising units of a monomer containing a carboxy group and units of a (meth) acrylic ester; (B) one or more, liquid or semisolid organic compounds which are compatible with the copolymer of the ingredient (A); and (C) at least one member selected among polyvalent-metal oxides and polyvalent-metal hydroxides, the total content of the ingredient (C) being 0.001-5 mass % based on the whole pressure-sensitive adhesive base. The adhesive base contains substantially no water. | 2009-11-05 |
20090274748 | Nonaqueous pressure-sensitive adhesive for medicinal tape preparation for percutaneous absorption, medicinal tape preparation for percutaneous absorption, and process for producing the same - A nonaqueous pressure-sensitive adhesive for a medicinal tape preparation for percutaneous absorption comprising (a) a support, (b) a pressure-sensitive adhesive layer containing a drug and a nonaqueous pressure-sensitive adhesive and (c) a release film laminated in that order, and a medicinal tape preparation for percutaneous absorption comprising the adhesive. The nonaqueous pressure-sensitive adhesive may comprise a copolymer obtained by copolymerization of a (meth)acrylic monomer having an acetoacetyl group in the molecule and one or more monomers from among other (meth)acrylic monomers without acetoacetyl groups and copolymerizable vinyl monomers, in a nonaqueous solvent. Suitable (meth)acrylic monomers having an acetoacetyl group in the molecule are acetoacetoxyalkyl methacrylates, and especially 2-acetoacetoxyethyl methacrylate. The copolymer nonaqueous pressure-sensitive adhesive of the invention, comprising a (meth)acrylic monomer having an acetoacetyl group as a constituent monomer, is capable of containing large amounts of lipophilic oily substances in the pressure-sensitive adhesive layer, and during heat drying, the acetoacetyl groups undergo self-crosslinking to form a network structure as the solvent evaporates off, so that large amounts of oily substances such as the plasticizer can be included in the network structure. The pressure-sensitive adhesive of the invention uses no polyamine derivatives, isocyanate compounds, polyvalent metal chelate compounds, etc., as crosslinking agents, and therefore toxicity is not a concern and skin is not irritated. A medicinal tape preparation for percutaneous absorption of the invention has superior adhesive strength and cohesive strength, and is highly safe with low skin irritation. It also has excellent drug release and percutaneous absorption properties. | 2009-11-05 |
20090274749 | Topical Application for Minimizing Melanin Production - Tyrosinase inhibitors are incorporated with liposomes in therapeutic compositions for topical application to hyperpigmentation. In particular, combinations of tyrosinase inhibitors are combined with liposomes to increase the penetration of the tyrosinase inhibitors into the deep epidermis skin layers and to provide hydration of the skin during treatment. | 2009-11-05 |
20090274750 | Therapeutic Treatment of Dermatologic Skin Disorders - Willowherb derivatives are incorporated with liposomes in therapeutic compositions for topical application to prevent or alleviate the conditions and symptoms of cosmetic and dermatologic disorders. In particular, willowherb derivates are combined with liposomes to increase the penetration of the willowherb derivates into the skin, to provide hydration of the skin during treatment. | 2009-11-05 |
20090274751 | Growth Factor Sensitive Vesicle - A generally spherical growth factor sensitive vesicle bearing growth factor receptors ( | 2009-11-05 |
20090274752 | COSMETIC AND DERMATOLOGICAL FORMULATIONS OF MNTF PEPTIDES - The disclosure is directed to methods and compositions that include MNTF peptides and their analogs for cosmetic and dermatological purposes. | 2009-11-05 |
20090274753 | PH-SENSITIVE POLYMERIC MICELLES FOR DRUG DELIVERY - Mixed micelles containing poly(L-histidine)-poly(ethylene glycol) block copolymer and poly(L-lactic acid)-poly(ethylene glycol) block copolymer are a pH-sensitive drug carrier that release the drug in an acidic microenvironment, but not in the blood. Since the microenvironment of solid tumors is acidic, these mixed micelles are useful for treating cancer, including those cancers exhibiting multidrug resistance. Targeting ligands, such as folate, can also be attached to the mixed micelles for enhancing drug delivery into cells. Methods of treating a warm-blooded animal with such a drug are disclosed. | 2009-11-05 |
20090274754 | DUAL ACTION, INHALED FORMULATIONS PROVIDING BOTH AN IMMEDIATE AND SUSTAINED RELEASE PROFILE - Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described. | 2009-11-05 |
20090274755 | Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals - The present invention is directed to a process for the catalytic oxidation of the thioether 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)methylthio)-1H-benzimidazole to its sulfoxide: 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl) methyl)methylsulfinyl)-1H-benzimidazole comprising: reacting the thioether with: 1) a transition metal catalyst; and, 2) an oxygen source; wherein the thioether is oxidized to a sulfoxide and wherein one of either the R and S enantiomers is formed to an enantiomeric excess. | 2009-11-05 |
20090274756 | Stabilized composition - It is intended to provide a pharmaceutical composition which contains a proton pump inhibitor and is stable even if it is stored for a long time. It is also intended to provide a pharmaceutical composition which contains a proton pump inhibitor susceptible to acid, and does not dissolve in the stomach but dissolves in the intestine to release a primary drug product promptly. The object could be achieved by the pharmaceutical composition characterized in that a layer containing a proton pump inhibitor and ethyl cellulose, a layer containing an enteric polymer, and if necessary an intermediate layer composed of one or more layers are formed on a pharmacologically inactive core substance. The intermediate layer is composed of a water-insoluble polymer, a water-soluble polymer, a lubricant and the like. | 2009-11-05 |
20090274757 | PHARMACEUTICAL POLISH FORMULATIONS - Polish compositions for coating pharmaceutical solid dosage forms such as tablets are disclosed. The polish composition comprises water, coating agent, and a film forming agent. Polished pharmaceutical solid dosage forms such as tablets comprising a polished exterior surface are also disclosed. Processes of polishing pharmaceutical solid dosage forms such as tablets are disclosed. | 2009-11-05 |
20090274758 | Solid Composition for Intra-Oral Delivery of Insulin - The invention provides a solid composition for intra-oral delivery of insulin, comprising; insulin; a hydrophilic polymer matrix; and a phospholipid, providing insulin bioavailability of at least 5%. | 2009-11-05 |
20090274759 | SOLID PHARMACEUTICAL COMPOSITION WITH A FIRST FRACTION OF A DISPERSION MEDIUM AND A SECOND FRACTION OF A MATRIX, THE LATTER BEING AT LEAST PARTIALLY FIRST EXPOSED TO GASTROINTESTINAL FLUIDS - A solid pharmaceutical composition in the form of a single dosage unit for oral use, the composition comprising a first and a second fraction, the first fraction comprises a therapeutically and/or prophylactically active substance dispersed in a dispersion medium that is sufficiently fluid at body temperature and the second fraction comprises a matrix comprising a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the first fraction being included in the composition in such a manner that at least a part of the second fraction is firstly exposed to the gastrointestinal fluids upon administration before the first fraction becomes exposed. The system is designed to release the active substance after a predetermined period of time after administration, and the release of the active substance at that point in time is relatively fast. | 2009-11-05 |
20090274760 | Use of An Alkyl Glycoside Or Of A Mixture Of Alkyl Glycosides Having Anti-Ageing And/Or Calming Properties As Active Agents In Cosmetic Compositions, And Methods Of Cosmetic Care Using Said Compositions - The present invention relates to a novel use of alkyl glycosides and of mixtures of alkyl glycosides having anti-ageing and/or calming properties as active agents in cosmetic compositions, and to methods of cosmetic care using the said compositions. | 2009-11-05 |
20090274761 | TRANSDERMAL DELIVERY OF (R)-3,3-DIPHENYLPROPYLAMIN-MONOESTERN - The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C | 2009-11-05 |
20090274762 | REHYDRATABLE PHARMACEUTICAL PRODUCT - A pharmaceutical product comprising lyophilised polymer matrix including a biologically active compound, of particular utility for embolisation, having improved rehydration properties is packaged in an airtight package under vacuum. | 2009-11-05 |
20090274763 | IMMUNOADJUVANT - An immunoadjuvant comprising one kind or two or more kinds of immunostimulating substances carried separately by two or more kinds of different microparticle immunostimulating substance carriers, and comprising at least a combination of (a) an inorganic substance such as microparticle calcium phosphate having a size phagocytizable by cells, and (b) precipitates of a soluble protein and a mucopolysaccharide formed by coacervation as the microparticle immunostimulating substance carriers, which is highly safe and can exhibit potent immunoadjuvant activity. | 2009-11-05 |
20090274764 | Hollow Foam Beads for Treatment of Glioblastoma - Compositions and methods for the treatment of tumors are disclosed. Specifically, the present invention provides hollow foam beads having a chemotherapeutic agent incorporated therein. A method of making such beads is disclosed. In addition, a method for treating a glioblastoma tumor and other types of tumors with the compressible hollow foam beads is disclosed. | 2009-11-05 |
20090274765 | Compositions and Methods for Drug Delivery - The present disclosure is directed to surface-modified particles and to methods of making and using the same. The surface-modified particles comprise a particle core and a coating associated with the particle core, wherein the particle core comprises an active agent, the coating comprises an opsonin, and the surface-modified particle has an average size from about 1 nm to about 2,000 nm. | 2009-11-05 |
20090274766 | Compositions and Methods For Inhibiting Gastric Acide Secretion Using Derivatives of Small Dicarboxylic Acids in Combination with PPI - The present invention is related to novel oral compositions comprising an irreversible gastric H | 2009-11-05 |
20090274767 | PLANT PROTECTION GRANULATES TO BE APPLIED TO LEAF SURFACE - The present invention relates to granules for application to the leaf surface, and to a process for their preparation. The invention furthermore relates to the use of these granules for foliar penetration or the formulation of baits. | 2009-11-05 |
20090274768 | FRAKTIONEN AUS MOLKEPERMEAT UND DEREN VERWENDUNG ZUR PRAVENTION UND THERAPIE DES TYP-2 DIABETES UND DES METABOLISCHEN SYNDROMS - Fractions of whey permeate, preferably made, of sweet whey permeate and more preferably of hydrolyzed or partially hydrolyze sweet whey permeate are provided, particularly for use in the production of pharmaceutical compositions, or of food, for the treatment, prophylaxis, or alleviation of glucose intolerance and insulin resistance, and thus of symptoms of the metabolic syndrome, type 2 diabetes, and complications in humans. | 2009-11-05 |
20090274769 | HEALING COMPOSITION - The invention relates to a ternary composition characterized in that it consists of a source of carbohydrates, a source of divided minerals, chosen from clays, and a source of fatty acids. It also relates to a healing composition comprising said ternary composition. In said compositions, the source of carbohydrates is chosen from honeys and the source of fatty acids is chosen from oils rich in linoleic acid and linolenic acid. | 2009-11-05 |
20090274770 | CELLULAR EXTRACTS - The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. This invention relates to the use of cells and cellular extracts in rejuvenation and healing technologies thereby improving healing and regeneration of all bodily tissues and organs. The present invention relates to compositions and methods of managing, preventing, and treating scars. The invention also relates to prevention of deterioration, damage and malfunction of cells and tissues, and to promote, improve or exceed cellular function in order to promote, improve and exceed appearance, vitality and health. In some embodiments, the invention relates to compositions of cells, eggs, cell extracts, egg extracts, and extract components such as purified nucleic acids, polypeptides, lipids, carbohydrates or other natural products. | 2009-11-05 |
20090274771 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS - Provided are compositions and methods for treating or preventing lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis (e.g. nose respiratory tract), and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically generated fluid (including gas-enriched electrokinetically generated fluids) as disclosed herein, the electrokinetically altered aqueous fluid suitable to alter cellular membrane structure or function sufficient to provide for modulation of intracellular signal transduction, wherein treating a lung disorder or a symptom thereof is thereby afforded. Additional aspects relate to therapeutic compositions, and combination treatment methods comprising administration of at least one electrokinetically generated fluid in combination with at least one additional therapeutic agent. | 2009-11-05 |
20090274772 | DISINFECTANT COMPOSITIONS AND METHODS OF USE THEREOF - The present invention discloses a highly potent, non-toxic, disinfectant that can be used for a wide breadth of applications. The disinfectant comprises hydrogen peroxide (H | 2009-11-05 |
20090274773 | ANTIPROLIFERATIVE COMBINATION COMPRISING CYC-682 AND A CYTOTOXIC AGENT - A first aspect of the invention relates to a combination comprising 2′-cyano-2′-deoxy-N4-palmitoyl-1-beta-D-arabi-nofuranosyl-cytosine, or a metabolite thereof, or a pharmaceutically acceptable salt thereof, and a cytotoxic agent selected from (a) a vinca alkaloid; (b) a taxane; (c) a cytosine analogue; (d) an anthracycline; and (e) a platinum antineoplastic agent. A second aspect of the invention relates to a pharmaceutical product comprising the above combination as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method for treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering the above combination. | 2009-11-05 |
20090274774 | Citrate-Based Dialysate Chemical Formulations - The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream. | 2009-11-05 |
20090274775 | Lithium combinations, and uses related thereto - The present invention relates to combinatorial therapies for treating anxiety, depression or psychotic conditions using a lithium salt and a psychoactive drug selected from the group consisting of serotonin reuptake inhibitor, a 5HT | 2009-11-05 |
20090274776 | Method for the Diagnosis and Treatment of Conditions Involving Aberrant Erythrocyte Potassium Levels - The present invention provides a systematic approach that allows health care providers (e.g., physicians) to use erythrocyte potassium measurements as an indicator of hypertension or risk of developing hypertension. In particular, the present invention provides systems and methods for treating conditions involving aberrant erythrocyte potassium levels (e.g., hypertension), preventing the onset of conditions involving aberrant erythrocyte potassium levels, identifying individuals at risk for developing hypertension, and evaluating the effectiveness of treatments for conditions involving aberrant erythrocyte potassium levels (e.g., hypertension). | 2009-11-05 |
20090274777 | Dietetic composition - (Problems) To provide a highly safe dietetic composition originating in green coffee beans by which excellent dietetic effects can be obtained and which contributes to the prevention and treatment of life style-related diseases such as diabetes. | 2009-11-05 |
20090274778 | Compositions Exhibiting Inhibition Of Cyclooxygenase-2 - The invention provides a method of treating diabetes by administering to an individual having diabetes a composition containing a hops extract. In a particular embodiment, an individual having diabetes can be administered a composition comprising a first component selected from the group consisting of alpha acids and beta acids, essential oils, fats and waxed, with the proviso that the first component and second component are not the same compound. The invention additional provides a method of treating diabetes by administering to an individual having diabetes a composition comprising a first component selected from a curcuminoid and a second component selected from an alpha acid and a beta acid. | 2009-11-05 |
20090274779 | Use in the cosmetics field of an extract of an exsudate of the plant daniellia oliveri, in particular as an antiwrinkle agent - The invention relates to the use, in a cosmetic composition or for the production of a cosmetic composition, of an extract of an exsudate of the plant | 2009-11-05 |
20090274780 | MENOPAUSE TREATMENT COMPOSITION AND REGIMEN - Disclosed are compositions and methods for treating symptoms associated with menopause and/or perimenopause. The compositions are based on a combination of concentrated extracts containing black cohosh, ginseng, red clover, soy isoflavones and St. John's wort, in the form of active compounds of these extracts. The treatment regimen, entail orally administering to a human subject suffering from symptoms of menopause and/or perimenopause, an effective dosage in effective amounts of the noted composition. | 2009-11-05 |
20090274781 | ANTI-OBESITY AGENT - The present invention provides an anti-obesity agent having an anti-obesity effect obtained by combining a few extracts, which is attained by an anti-obesity agent containing Forsythia leaf extract, Citrus extract, and at least one extract selected from the group consisting of Licorice extract and Gardenia fruit extract, and it is preferable that the anti-obesity agent contains both Licorice extract and Gardenia fruit extract. The anti-obesity agent exhibits an ideal anti-obesity effect for increasing brown adipocytes and muscle weight to increase a basal metabolic rate and to decrease white adipocytes. | 2009-11-05 |
20090274782 | ANTI-OBESITY AGENT - The present invention provides an anti-obesity agent having an anti-obesity effect obtained by combining a few extracts, which is attained by an anti-obesity agent (FC) containing Forsythia leaf extract and Citrus extract, and, in addition to these extracts, the anti-obesity agent containing Forsythia leaf extract, Citrus extract, and one extract selected from the group consisting of Licorice extract (FCGr) and Gardenia fruit extract (FCGf). These anti-obesity agents exhibited an ideal anti-obesity effect of decreasing white adipocytes while maintaining a basal metabolic rate without having a significant effect on brown adipocytes. | 2009-11-05 |
20090274783 | HERBAL COMPOSITIONS AND METHODS FOR ENHANCING VITAL ENERGY AND ATHLETIC PERFORMANCE - Compositions, kits and methods are provided for enhancing vital energy and athletic performance, improving or restoring blood circulation, promoting mental acuity, reducing fatigue, and improving aerobic performance. In one embodiment, the composition comprises the herbal extracts of | 2009-11-05 |
20090274784 | PLANT EXTRACT MIXTURES AND THEIR USES - In one embodiment, a composition containing an effective amount of Cissus quadrangularis and one or more plants selected from the Brillantaisia and Vernonia plant families whereby the composition reduces the amount of fat absorbed or reduces weight in a mammal. Such compositions have beneficial activity principally in controlling weight gain and obesity, especially in conjunction with chitosan or a chitosan derivative and an antioxidant such as vitamin C. | 2009-11-05 |
20090274785 | METAL POWDER PRODUCTION APPARATUS AND METAL POWDER - A metal powder production apparatus is capable of efficiently producing fine metal powder with a uniform particle size. The metal powder produced by the apparatus has an increased quality. The apparatus (atomizer) makes use of an atomizing method to pulverize molten metal into metal powder. The apparatus includes a supply part (tundish) for supplying the molten metal, a nozzle provided below the supply part, a tubular member provided between the supply part and the nozzle. The tubular member is constructed to ensure that the molten metal ejected from an ejection port passes through a bore of the tubular member and then makes contact with a fluid jet. Further, the tubular member has a top end air-tightly connected to the supply part and a bottom end lying around the midway of a first flow path through which the molten metal passes. | 2009-11-05 |
20090274786 | Device for Extruding a Strip of Rubber - A device for extruding a strip of rubber comprises a passage for forming the strip, which passage is defined by a rotary roller for forming and driving the strip. The device also comprises a shutter for shutting the forming passage, which shutter is deactivatable under the effect of the pressure of the rubber upstream from the shutter exceeding a predetermined threshold. | 2009-11-05 |
20090274787 | Open Loop Pressure Control for Injection Molding - An injection molding system is disclosed having a self-regulating valve for balancing melt flow. The self-regulating valve includes a control rod configured to balance the melt flow rate through a hot runner system. The self-regulating valve reacts to an injection or melt pressure within the hot runner system and a pre-set force provided by an external force device. The self-regulating valve is an open-loop system as it requires neither a measurement of pressure by a sensor nor feedback from a processor in order to regulate the melt flow. The self-regulating valve mechanically reacts to changes in melt pressure on control surfaces thereof by “bobbing” upwards/downwards to decrease/increase the melt flow accordingly. The self-regulating valve compensates for conditions that affect melt pressure, such as an increase/decrease in melt viscosity, changes in melt temperature, and/or mold cavity size without the use of a processing device. | 2009-11-05 |
20090274788 | DEVICE FOR PRODUCING A CONTAINER - The method comprises the following steps: a) the container opening is sealed, b) at least one wall opening is created by drilling through or piercing the wall of the outer container using a drill, graver or needle, a pressurized medium being introduced into the gap between the outer container and the inner tube, once the wall of the outer container has been fully penetrated, c) the advance of the drill or needle is halted as soon as a predetermined first pressure threshold has been reached in the inner tube, d) the introduction of the pressurized medium into the gap between the outer container and the inner tube is halted as soon as a predetermined second pressure threshold has been reached in the inner tube, e) once the pressure in the gap between the outer container and the inner tube has been relieved, a pressurized medium is introduced into the inner tube through the container opening, in order to place the inner tube against the container wall again after it has been detached from the latter. The method allows the inner tube to be detached in a controlled manner with a high degree of uniformity from the outer container and to be placed against said outer container again without a significant inclusion of air. | 2009-11-05 |
20090274789 | INJECTION/STRETCH BLOW MOLDING MACHINE - Provided is an injection/stretch blow molding machine, which performs both injection molding of a preform and stretch blow molding of a hollow molded product continuously within single machine. In an injection/stretch blow unit used in the injection/stretch blow molding machine, an injection mold clamping mechanism comprises a mold clamping shafts erected vertically movably on both sides of an injection molding operation section and extending through both a lower base platen and an upper base platen, hydraulic mold clamping means connected respectively to lower ends positioned within a bed of the mold clamping shafts, a mold clamping platen having core molds attached thereto downwards and being fitted and supported at both ends thereof on the mold clamping shafts, the mold clamping platen being installed vertically movably between the upper base platen and a top platen disposed on upper ends of the shafts, a pair of mold opening/closing air cylinders connecting on both sides thereof the upper base platen and the mold clamping platen with each other and causing the mold clamping platen to move vertically with respect to the upper base platen, a mold clamping rod connected to the mold clamping platen through the top platen, and a pair of clamp members disposed on an upper surface of the top platen, the clamp members being adapted to fit with the mold clamping rod pneumatically to connect the mold clamping platen and the mold clamping shafts with each other. In an injection molding operation section, a stretch blow molding operation section and a take-out operation section, edge sides of the upper base platen and a transfer platen are formed as U-shaped recesses and neck molds are positioned within the recesses by bridgewise mounting of mold holding plates over the recesses. | 2009-11-05 |
20090274790 | SHOOTING POT FOR FEEDING MULTIPLE NOZZLES - A hot runner system including a shoot pot system for transferring melt from a single shooting pot to multiple nozzles. Melt is fed from a source of melt into the cavity through the multiple nozzles, and a valve isolates melt in the cavity from melt in the source. A plunger within the cavity is driven forward to inject melt in the cavity into a mold cavity at high pressure without significantly increasing the pressure of melt in the source. The plunger optionally functions as both the plunger and the valve by opening and closing communication between the cavity and the manifold as it is rotated. | 2009-11-05 |
20090274791 | Food Articles With Delivery Devices and Methods for the Preparation Thereof - Disclosed are food articles comprising delivery devices. Methods of preparing such food articles are also disclosed. | 2009-11-05 |
20090274792 | Novel bacterial phytases and method for producing same - The invention concerns novel bacterial phytases, and their respective production methods. More particularly, the invention concerns novel phytases derived from bacteria of genus | 2009-11-05 |
20090274793 | Wine Making Method - In a method of making wine comprising fermenting a mixture in a main batch container to produce wine and transferring the wine from the main batch container to a plurality of bottles, at least a portion of the wine is exposed to a vacuum pressure during the wine making process prior to bottling. The wine is thus degassed without the stress of agitation or filtering being required. The wine is also transferable either for racking to remove sediment or when bottling in a manner which reduces sediment uptake into the siphon tubes and which reduces stress from agitations applied to the wine using vacuum pressure. | 2009-11-05 |
20090274794 | Gene Encoding Cell Wall Mannoprotein and use Thererof - The present invention relates to a brewer's yeast which produces alcoholic beverages having an ability for reducing the haze level, alcoholic beverages produced using such a yeast, and a method of producing such alcoholic beverages. More specifically, the present invention relates to a yeast which can reduce the level of haze in the product by increasing the level of expression of ScCWP2 gene encoding cell wall mannoprotein Cwp2p in brewer's yeast, or non-ScCWP2 gene characteristic to beer yeast, and to a method of producing alcoholic beverages using such a yeast. | 2009-11-05 |
20090274795 | Enzyme Granulate l Containing Phytase - The present invention relates to novel phytase-comprising enzyme granules, those particles of which have
| 2009-11-05 |
20090274796 | Methods for Enhancing Palatability of Compositions for Animal Consumption - Zeolite is added to animal food compositions in amounts sufficient to enhance palatability, preferably in amounts of from about 0.01% to about 4% by weight of the composition. The compositions containing zeolite are ingested more frequently and at a higher rate by animals, particularly finicky animals or older animals that tend not to eat enough food to maintain their health. | 2009-11-05 |
20090274797 | HIGH FIBER PASTRY PRODUCT - High fiber-containing pastry products are described. The high fiber-containing pastry products typically comprise about 5-10 grams of fiber in a 54 gram serving of the pastry. The high fiber-containing pastry products comprise a fried laminated dough piece prepared from a developed dough that comprises, inter alia, wheat flour, resistant wheat starch, and vital wheat gluten. The use of a reduced amount of wheat flour along with the addition of resistant wheat starch and vital wheat gluten enables the production of a dough composition that has a high fiber content while retaining desirable organoleptic and processing characteristics. | 2009-11-05 |
20090274798 | Frozen aerated product - The present invention relates to a frozen aerated product comprising a soy product, which comprises soy protein and less than 25 weight-% (wt-%), based on the total weight of the soy product, of soy fat and at least one destabilising emulsifier: as well as to a process for the production of such a frozen aerated product. | 2009-11-05 |
20090274799 | Seasoning Bag - A bag for applying seasoning to a food item is provided. The bag comprises a mouth, an interior surface, and a seasoning. The mouth receives the food item, and the seasoning is adhered to at least a portion of the interior surface such that the food item may be seasoned if placed through the mouth into the bag. In another embodiment, the bag may comprise a compartment for holding a seasoning. The compartment may have a releasable seal to release the seasoning on the food item. The bag may be provided to the consumer in a container such that the consumer may remove the bag from the container and place a food item in the bag to season the food item. | 2009-11-05 |
20090274800 | PET FOOD PRODUCT WITH FLAVORING - A commercial packeted pet food product, having: an edible substrate, said substrate including at least one surface adapted to receive a suspension of flavorsome materials in a paste, gum or gel; and flavorsome materials, adhering to said surface, which substantially contribute to producing the flavor profile of said pet food product when consumed. | 2009-11-05 |
20090274801 | Cup shaped baked confectionary and manufacturing method thereof - A cup shaped baked confectionary has light texture, uniform thickness and easy to release from the die. The cup shaped baked confectionary may be produced by mounting a dough of a cup shaped baked confectionary having desired contour shape on a top of a metallic three-dimensional baking die having desired shape of outer peripheral surface, in a condition extending horizontally with placing outer periphery thereof outside of the three dimensional baking die and heating the dough for softening the dough of the cup shaped baked confectionary to contact on the outer peripheral surface of the three-dimensional baking die and baking. | 2009-11-05 |
20090274802 | Method for the Intelligent Continuous Filling of a Cooking Device and Cooking Device Therefor - A method for managing cooking programs first comprises selecting, at a point in time (t | 2009-11-05 |
20090274803 | METHOD TO PRE-CRYSTALLIZE REAL CHOCOLATE IN THE FORM OF STABLE BETA V POLYMORPHIC CRYSTALS - The present invention relates to a method to pre-crystallize real chocolate in the form of Beta V crystals, said method comprising the steps of—determining an initial temperature (TCi) for a chocolate mass to have before seed crystals are admixed thereto, said TCi exceeding the critical temperature, —obtaining a liquid chocolate mass by melting it to the initial temperature (TCi), —dispersing into said liquid chocolate mass at the initial temperature (TCi), solid crystal seeds consisting of at least one ingredient selected from the group consisting of cocoa butter, a cocoa butter equivalent and/or real chocolate, wherein the crystal seeds contain a dominating amount of stable Beta V crystals, —mixing the chocolate mass and the crystal seeds until the seeds are almost completely melted, —cooling down the thus obtained mixture, that is continuously stirred, to a pre-crystallization temperature (Tpc), said cooling being achieved through the admixing of the crystal seeds and through heat exchange with the environment to form a pre-crystallized chocolate, and—optionally maintaining the thus obtained mixture at the pre-crystallization temperature to maintain the chocolate mass in a pre-crystallized state. The present invention further relates to methods and means to determine the TCi needed to reach the pre-crystallization temperature within an acceptable time (e.g. within less than 6 minutes). | 2009-11-05 |
20090274804 | SYSTEMS, METHODS AND DEVICES FOR USE IN ASSESSING CARCASS GRADING - Methods, systems and devices are implemented in connection with measuring the relative content of intramuscular fat (IMF) in a portion of muscle tissue. Consistent with one such method a probe is presented to the portion of muscle tissue. The probe produces a response-provoking signal in the muscle tissue. A resulting signal is used to determine the relative content of IMF in the portion of muscle tissue as a function of the pressure being exerted between the probe and the portion. | 2009-11-05 |
20090274805 | METHOD AND COOKING APPLIANCE FOR REGULATING A COOKING PROCESS IN A COOKING CHAMBER - In one embodiment for regulating a baking process in an oven, an operator introduces a product to be cooked into the oven, and a sensor detects a gas or moisture concentration release from the product cooking in the cooking chamber over time wherein The slope of the curve of the detected concentration is determined, and a trigger value that is linked to the product to be cooked is determined for the slope. The point in time at which the trigger value will be reached is determined, and an additional time linked to said point in time is determined at the point in time at which the trigger value is reached. The additional time depends on the point in time at which the trigger value is reached. The additional time is continued as an additional process until the additional time has elapsed in case the trigger value is not reached. | 2009-11-05 |
20090274806 | METHOD AND APPARATUS FOR VITAMIN D ENHANCEMENT IN MUSHROOMS - An apparatus and method for increasing Vitamin D content in mushrooms irradiates the mushroom(s) for a duration of up to six seconds with one or more pulses of light with wavelengths in the range of about 200 to about 1000 nanometers. The light is emitted by an electric glow discharge lamp, such as a xenon lamp, that emits ultra-violet light. The intensity of the light is such that after irradiation the mushrooms have a Vitamin D2 content of at least about 400 IU/84 g of mushrooms, which is 100% Daily Value of recommended Vitamin D for human consumption. | 2009-11-05 |